DelveInsight’s, “Phosphatidylinositol 3 Kinase Delta Inhibitors - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in “Phosphatidylinositol 3 Kinase Delta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Phosphatidylinositol 3 Kinase Delta Inhibitors: Overview
A phosphoinositide 3-kinase inhibitor (PI3K inhibitor) is a class of medical drug that functions by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are part of the PI3K/AKT/mTOR pathway, an important signalling pathway for many cellular functions such as growth control, metabolism and translation initiation. Within this pathway there are many components, inhibition of which may result in tumor suppression. These anti-cancer drugs are examples of targeted therapy.
The companies and academics are working to assess challenges and seek opportunities that could influence “Phosphatidylinositol 3 Kinase Delta Inhibitors R&D. The therapies under development are focused on novel approaches for “Phosphatidylinositol 3 Kinase Delta Inhibitors.
This segment of the “Phosphatidylinositol 3 Kinase Delta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Phosphatidylinositol 3 Kinase Delta Inhibitors Emerging Drugs
Umbralisib: TG Therapeutics
Umbralisib (TGR-1202) is an oral inhibitor of PI3K-delta and CK1-epsilon administered once daily. Umbralisib is presently being evaluated in patients with Non-Hodgkin's lymphoma (NHL) and Chronic lymphocytic leukaemia (CLL) in combination with other agents including ublituximab. The phosphoinositide-3-kinases (PI3Ks) are a family of enzymes involved in many important cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking, and immunity.
Parsaclisib: Incyte Corporation
Parsaclisib is a potent, highly selective, next-generation investigational novel oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). It is currently under evaluation as a monotherapy in several ongoing Phase 2 trials as a treatment for non-Hodgkin lymphomas (follicular, marginal zone and mantle cell); and autoimmune hemolytic anemia. Pivotal trials of parsaclisib in combination with ruxolitinib for the treatment of patients with myelofibrosis are underway; and there are plans to initiate a trial to evaluate parsaclisib in combination with tafasitamab for B-cell malignancies. In December 2018, Innovent and Incyte entered into a strategic collaboration for three clinical-stage product candidates, including parsaclisib. Under the terms of the agreement, Innovent has received the rights to develop and commercialize parsaclisib and two other assets in Mainland China, Hong Kong, Macau and Taiwan.
Further product details are provided in the report……..
This segment of the report provides insights about the different Phosphatidylinositol 3 Kinase Delta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 20+ key companies which are developing the Phosphatidylinositol 3 Kinase Delta Inhibitors. The companies which have their “Phosphatidylinositol 3 Kinase Delta Inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, TG Therapeutics.
DelveInsight’s report covers around 20+ products under different phases of clinical development like
Phosphatidylinositol 3 Kinase Delta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses “Phosphatidylinositol 3 Kinase Delta Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging “Phosphatidylinositol 3 Kinase Delta Inhibitors drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Phosphatidylinositol 3 Kinase Delta Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Phosphatidylinositol 3 Kinase Delta Inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Umbralisib: TG Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tenalisib: Rhizen Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
ZX 101A: Nanjing Zenshine Pharmaceuticals
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
AT-104: Applied Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Phosphatidylinositol 3 Kinase Delta Inhibitors Key Companies
Phosphatidylinositol 3 Kinase Delta Inhibitors Key Products
Phosphatidylinositol 3 Kinase Delta Inhibitors- Unmet Needs
Phosphatidylinositol 3 Kinase Delta Inhibitors- Market Drivers and Barriers
Phosphatidylinositol 3 Kinase Delta Inhibitors- Future Perspectives and Conclusion
Phosphatidylinositol 3 Kinase Delta Inhibitors Analyst Views
Phosphatidylinositol 3 Kinase Delta Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Phosphatidylinositol 3 Kinase Delta Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Phosphatidylinositol 3 Kinase Delta Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• TG Therapeutics
• Incyte Corporation
• Nanjing Zenshine Pharmaceuticals
• Shanghai Yingli Pharmaceutical
• Bayer HealthCare Pharmaceuticals
• Novartis
• Rhizen Pharmaceuticals
• Secura Bio
• Applied Therapeutics
• Hillstream BioPharma
• Celon pharma
• Yuhan
• Gilead Sciences
• Chia Tai Tianqing Pharmaceutical Group
• Acerta Pharma
• BR 101801
• BeiGene
• Nanjing Sanhome Pharmaceutical
• Hutchison MediPharma
• Calistoga Pharmaceuticals
• Kyowa Kirin
